title: The immune space: a concept and template for rationalizing vaccine development.
abstract: Empirical testing of candidate vaccines has led to the successful development of a number of lifesaving vaccines. The advent of new tools to manipulate antigens and new methods and vectors for vaccine delivery has led to a veritable explosion of potential vaccine designs. As a result, selection of candidate vaccines suitable for large-scale efficacy testing has become more challenging. This is especially true for diseases such as dengue, HIV, and tuberculosis where there is no validated animal model or correlate of immune protection. Establishing guidelines for the selection of vaccine candidates for advanced testing has become a necessity. A number of factors could be considered in making these decisions, including, for example, safety in animal and human studies, immune profile, protection in animal studies, production processes with product quality and stability, availability of resources, and estimated cost of goods. The "immune space template" proposed here provides a standardized approach by which the quality, level, and durability of immune responses elicited in early human trials by a candidate vaccine can be described. The immune response profile will demonstrate if and how the candidate is unique relative to other candidates, especially those that have preceded it into efficacy testing and, thus, what new information concerning potential immune correlates could be learned from an efficacy trial. A thorough characterization of immune responses should also provide insight into a developer's rationale for the vaccine's proposed mechanism of action. HIV vaccine researchers plan to include this general approach in up-selecting candidates for the next large efficacy trial. This "immune space" approach may also be applicable to other vaccine development endeavors where correlates of vaccine-induced immune protection remain unknown.
authors.affiliation: 1 Global HIV Vaccine Enterprise , New York, New York.
authors.forename: Amapola
authors.initials: A
authors.lastname: Manrique
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Adams
authors.forename: Dan H
authors.initials: DH
authors.lastname: Barouch
authors.forename: Pat
authors.initials: P
authors.lastname: Fast
authors.forename: Barney S
authors.initials: BS
authors.lastname: Graham
authors.forename: Jerome H
authors.initials: JH
authors.lastname: Kim
authors.forename: James G
authors.initials: JG
authors.lastname: Kublin
authors.forename: Margaret
authors.initials: M
authors.lastname: McCluskey
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pantaleo
authors.forename: Harriet L
authors.initials: HL
authors.lastname: Robinson
authors.forename: Nina
authors.initials: N
authors.lastname: Russell
authors.forename: William
authors.initials: W
authors.lastname: Snow
authors.forename: Margaret I
authors.initials: MI
authors.lastname: Johnston
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic; D003141:Communicable Diseases / Q000453:epidemiology*; D055808:Drug Discovery / Q000379:methods* / Q000592:standards*; D006801:Humans; D014611:Vaccination / Q000379:methods; D014612:Vaccines / Q000009:adverse effects / Q000276:immunology* / Q000302:isolation & purification*
chemical_list: D014612:Vaccines